Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
April 3, 2019
Lipocine Seeks Injunction Against the Marketing of Clarus Therapeutics' JATENZO® for Testosterone Replacement Therapy
SALT LAKE CITY, April 3, 2019 /PRNewswire/ -- Lipocine Inc.(LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has filed ...
March 27, 2019
Orchard Therapeutics Presents New Registrational Data Demonstrating Sustained Clinical Benefit of OTL-200 for the Treatment of MLD
BOSTON and LONDON, March 27, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with ...
March 27, 2019
DURECT Announces Patient Enrollment in Phase 1b Clinical Trial of Oral DUR-928 in Patients with Non-Alcoholic Steatohepatitis (NASH)
CUPERTINO, Calif., March 27, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) today announced it has commenced patient enrollment in a Phase 1b trial with oral DUR-928 ...
March 27, 2019
Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)-- Urovant Sciences (UROV), a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for urologic conditions, today announced that it ...
March 27, 2019
Lipocine Announces ABPM Labeling Study Results Consistent with Recently Approved Testosterone Replacement Therapy
SALT LAKE CITY, March 27, 2019 /PRNewswire/ -- Lipocine Inc.(LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced findings from the Ambulatory ...
March 27, 2019
CymaBay Therapeutics Announces Multiple Presentations During The International Liver Conference™ 2019
NEWARK, Calif., March 27, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), today announced that multiple seladelpar presentations will be delivered during The International Liver ...
March 27, 2019
Clinical Outcomes Data on SkinTE™ from Lower Extremity Chronic Wounds to be Presented at Diabetic Limb Salvage (DLS) Conference
SALT LAKE CITY, March 27, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that two ...
March 27, 2019
TRACON Pharmaceuticals Announces TRC105, TRC253 and TRC102 Data Presentations at Upcoming AACR Annual Meeting
SAN DIEGO, March 27, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
March 27, 2019
Albireo to Present Clinical Data on A4250 in Alagille Syndrome and Biliary Atresia at The International Liver Congress™ 2019
BOSTON, March 27, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
March 27, 2019
Brainsway Reports Financial Results for Fourth Quarter and Full-Year 2018
HACKENSACK, N.J., March 27, 2019 (GLOBE NEWSWIRE) -- Brainsway Ltd. (BRIN.TA), a leader in the advanced non-invasive treatment of brain disorders, has issued the Company’s ...
March 27, 2019
Entera Bio to Announce Fourth Quarter and Year Ended December 31, 2018 Financial Results on Thursday, March 28
JERUSALEM, March 27, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (ENTX), announced today that it will report financial results for the fourth quarter and year ...
March 27, 2019
Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast
SYDNEY, Australia, March 27, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments ...
March 26, 2019
ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership
LEIDEN, Netherlands and CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of ...
March 26, 2019
Pfenex to Present at the 18th Annual Needham Healthcare Conference
SAN DIEGO, March 26, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex ...
March 26, 2019
CorMedix Confirms Previously Announced One-For-Five Reverse Stock Split
BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 25, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products ...
March 26, 2019
BioInvent and Transgene Extend Their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
LUND, Sweden and STRASBOURG, France, March 26, 2019/PRNewswire/ -- BioInvent International AB (OMXS:BINV), a biotech company focused on the discovery and development of novel immuno-regulatory ...
March 26, 2019
InspireMD Announces 1-for-50 Reverse Stock Split
TEL AVIV, Israel, March 26, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), a leader in embolic prevention systems (EPS) / thrombus ...
March 26, 2019
iCAD to Present Corporate Overview at the Jefferies 2019 Radiation Oncology & Energy-Based Therapeutics Summit
NASHUA, N.H., March 26, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that ...
March 26, 2019
Eiger BioPharmaceuticals to Participate in Conferences in April
PALO ALTO, Calif., March 26, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare ...
March 26, 2019
Lipocine Late-Breaker Presentation at EASL Meeting to Detail LPCN 1144 MRI-PDFF Based Clinical Results on Reduction of Liver Fat and Key Serum Biomarkers
SALT LAKE CITY, March 26, 2019 /PRNewswire/ -- Lipocine Inc.(LPCN), a specialty pharmaceutical company, announced today acceptance of their abstract for late-breaker presentation on LPCN 1144 ...
Page 3 of 138